The present disclosure relates to methods of transition-ing patients or obese patients being treated with vortioxetine to treatmentwith a monoamine oxidase inhibitor (MAOI). The methods provided includedelaying administration of the MAOI for certain timeperiods after stopping administration of vortioxetine. The patients orobese patients possess various capabilities of metabolizing vortioxetine.The cunent disclosure also includes methods of switching patientsto a MAOI intended to treat psychiatric disorders while being treatedwith vortioxetine. The methods disclosed further comprise determiningvortioxetine plasma clearance and washout time for patients withdifferent body fat status and/or different CYP2D6 metabolizer status.
